Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Widemann Website

Brigitte C. Widemann, M.D.

Selected Publications

1)  Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, Salzer W, Gillespie A, Baldwin A, Derdak J, Widemann B.
18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
Pediatr Blood Cancer. 60: 59-64, 2013.
[Journal]
2)  Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N.
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
J. Clin. Invest. 123: 340-7, 2013.
[Journal]
3)  Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC.
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Pediatr Blood Cancer. 60: 396-401, 2013.
[Journal]
4)  Avery RA, Dombi E, Hutcheson KA, Acosta MT, Baldwin AM, Madigan WP, Gillespie A, Fitzgibbon EJ, Packer RJ, Widemann BC.
Visual Outcomes in Children With Neurofibromatosis Type 1 and Orbitotemporal Plexiform Neurofibromas.
Am. J. Ophthalmol. [Epub ahead of print], 2013.
[Journal]
5)  Lodish M, Dagalakis U, Chen CC, Sinaii N, Whitcomb P, Aikin A, Dombi E, Marcus L, Widemann B, Fox E, Chuk M, Balis F, Wells S, Stratakis CA.
(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents.
J. Clin. Endocrinol. Metab. 97: E207-12, 2012.
[Journal]
6)  Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E.
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Pediatr Blood Cancer. 59: 865-9, 2012.
[Journal]
7)  Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM.
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children"s Oncology Group Phase I Consortium report.
Clin. Cancer Res. 18: 6011-22, 2012.
[Journal]
8)  Lodish MB, Dagalakis U, Sinaii N, Bornstein E, Kim A, Lokie KB, Baldwin AM, Reynolds JC, Dombi E, Stratakis CA, Widemann BC.
Bone mineral density in children and young adults with neurofibromatosis type 1.
Endocr. Relat. Cancer. 19: 817-25, 2012.
[Journal]
9)  Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, Friedman JM, Mautner VF.
Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.
Orphanet J Rare Dis. 7: 75, 2012.
[Journal]
10)  Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, Amaoko M, Rhee EH, Price A, Wexler LH, Meyers PA, Widemann BC, Tsokos M, Mackall CL.
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.
J. Clin. Oncol. 30: 4141-7, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/3/2013.